Table 6.
The prevalences of BRAF V600E and KRAS mutations in serrated and non-serrated adenomas and adenocarcinomas with high-level microsatellite instability (MSI-H) and microsatellite stability (MSS)/low-level microsatellite instability (MSI-L)
| Mutation | All, N | MSS/MSI-L, n (%) | MSI-H, n (%) | P-value (Fisher's exact test) | |
|---|---|---|---|---|---|
| All CRC | BRAF V600E mutation | 12 | 7 (58.3) | 5 (41.7) | 0.007 |
| KRAS c12/13 or c59/61 mutation | 31 | 30 (96.8) | 1 (3.2) | ||
| Wild type | 31 | 26 (83.9) | 5 (16.1) | ||
| Serrated CRC with their matched controls | BRAF V600E mutation | 12 | 7 (58.3) | 5 (41.7) | 0.008 |
| KRAS c12/13 or c59/61 mutation | 29 | 28 (96.5) | 1 (3.5) | ||
| Wild type | 23 | 18 (78.3) | 5 (21.7) | ||
| Serrated CRC | BRAF V600E mutation | 12 | 7 (58.3) | 5 (41.7) | 0.075 |
| KRAS c12/13 or c59/61 mutation | 16 | 15 (93.8) | 1 (6.2) | ||
| Wild type | 6 | 5 (83.3) | 1 (16.7) | ||
| Non-serrated CRC | BRAF V600E mutation | 0 | 0 (0) | 0 (0) | 0.278 |
| KRAS c12/13 or c59/61 mutation | 15 | 15 (100) | 0 (0) | ||
| Wild type | 25 | 21 (84) | 4 (16.0) | ||
| Matched non-serrated CRCs | BRAF V600E mutation | 0 | 0 (0) | 0 (0) | 0.113 |
| KRAS c12/13 or c59/61 mutation | 13 | 13 (100) | 0 (0) | ||
| Wild type | 17 | 13 (76.5) | 4 (23.5) | ||
| All adenomas | BRAF V600E mutation | 4 | 4 (100) | 0 (0) | 0.588 |
| KRAS c12/13 or c59/61 mutation | 7 | 7 (100) | 0 (0) | ||
| Wild type | 6 | 5 (83.3) | 1 (16.7) | ||
| Serrated adenomas | BRAF V600E mutation | 4 | 4 (100) | 0 (0) | NA |
| KRAS c12/13 or c59/61 mutation | 7 | 7 (100) | 0 (0) | ||
| Wild type | 2 | 2 (100) | 0 (0) | ||
| Non-serrated adenomas | BRAF V600E mutation | 0 | 0 (0) | 0 (0) | NA |
| KRAS c12/13 or c59/61 mutation | 0 | 0 (0) | 0 (0) | ||
| Wild type | 4 | 3 (75) | 1 (25.0) | ||
CRC, Colorectal carcinoma; NA, not applicable.